Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

• Verfasst von: Sahebi, Firoozeh [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Schönland, Stefan [VerfasserIn]
• Titel: Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
• Verf.angabe: F Sahebi, S Iacobelli, AV Biezen, L Volin, P Dreger, M Michallet, PT Ljungman, T de Witte, A Henseler, NPM Schaap, L López-Corral, X Poire, J Passweg, R-M Hamljadi, SH Thomas, S Schonland, G Gahrton, C Morris, N Kröger and L Garderet on behalf of the Plasma Cell Disorders Subcommittee of the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party
• E-Jahr: 2015
• Jahr: 23 March 2015
• Umfang: 6 S.
• Fussnoten: Gesehen am 04.04.2017
• Titel Quelle: Enthalten in: Bone marrow transplantation
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2015
• Band/Heft Quelle: 50(2015), 6, Seite 802-807
• ISSN Quelle: 1476-5365
• DOI: doi:10.1038/bmt.2015.45
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1556270089

Abstract

We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.